<DOC>
	<DOCNO>NCT01098084</DOCNO>
	<brief_summary>The aim study determine therapeutic efficacy Decitabine patient chronic myelomonocytic leukemia ( CMML ) diagnosis accord WHO criteria either untreated previously treat Hydrea Etoposide ( give orally ) , non intensive chemotherapy intensive chemotherapy give 3 month inclusion .</brief_summary>
	<brief_title>Decitabine Patients With Chronic Myelomonocytic Leukemia ( CMML )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Age 18 old CMML diagnosis accord WHO criteria Stable excess blood monocyte , &gt; 1x10G/l &gt; 10 % WBC Bone marrow blast &lt; 20 % Dysplasia least one lineage clonality marker blood monocytosis 3 month w/o explanation With : WBC &lt; or= 12 000/mm3 : IPSS high intermediate 2 WBC &gt; 12 000/mm3 : least two follow criterion : blast cell &gt; 5 % bone marrow , clonal cytogenetic abnormality ( 5 ; 12 ) ( q33 ; p13 ) , anemia ( Hb &lt; 100 g/l ) , thrombocytopenia ( platelet count &lt; 100G/l ) , splenomegaly &gt; 5 cm costal margin , extramedullary localization Either untreated previously treat Hydrea Etoposide give orally non intensive chemotherapy intensive chemotherapy give 3 month inclusion With performance status 02 ECOG scale With estimate life expectancy least 12 week With adequate organ function include following : Hepatic : total bilirubin &lt; 1.5 time upper limit normal ( ULN ) , alanine transaminase ( ALT ) aspartate transaminase ( AST ) &lt; 3 time ULN Renal : serum creatinine &lt; 1.5 time ULN , creatinine clearance &gt; 30 ml/min With informed consent Negative pregnancy adequate contraception relevant Myeloproliferative/myelodysplastic syndrome CMML Acute blastic transformation CMML bone marrow blast &gt; 20 % Patients eligible allogenic bone marrow transplantation identify donor CMML ( 5 ; 12 ) PDGFbetaR rearrangement could receive Imatinib Previous treatment hypomethylating agent Age &lt; 18 year old Pregnancy breastfeed Performance status &gt; 2 ECOG Scale Estimated life expectancy &lt; 12 week Serious concomitant systemic disorder , include active bacterial , fungal viral infection , opinion investigator would compromise safety patient and/or his/her ability complete study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Decitabine , chronic myelomonocytic leukemia</keyword>
</DOC>